CERC Cerecor Inc.

5.05
0  0%
Previous Close 5.05
Open
Price To Book 9.35
Market Cap 215,905,978
Shares 42,753,659
Volume 0
Short Ratio
Av. Daily Volume 97,769

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data released December 5, 2016 - endpoint not met.
CERC-501
Smoking cessation
Phase 2 top-line data released November 29, 2016 failed to meet primary endpoint.
CERC-301
Major depressive disorder (MDD)
Phase 1 trial to be completed June 2019.
CERC-301
Neurogenic Orthostatic Hypotension (nOH)
Phase 1 Pharmacokinetic (PK) data due summer 2019.
CERC 801
Phosphoglucomutase 1 (PGM1) deficiency

Latest News

  1. Cerecor Appoints Keith Schmidt to its Board of Directors
  2. Cerecor Set to Join Russell 3000® Index
  3. CERC: Completion of Phase 1 Trial of CERC-801…
  4. Cerecor Reports First Quarter 2019 Results
  5. Introducing Cerecor (NASDAQ:CERC), A Stock That Climbed 42% In The Last Three Years
  6. Cerecor Announces Positive Phase I Safety Data for CERC-801 in Healthy Volunteers
  7. CERC: Positive Results for Phase 1 Trial of CERC-301…
  8. Cerecor Announces Positive Interim Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (nOH)
  9. Cerecor Announces Leadership Changes
  10. CERC: Multiple Data Readouts in 2019; Commercial Unit Continues Growth…
  11. Cerecor Reports Fourth Quarter and Full Year 2018 Results
  12. Cerecor Increases Previously Announced Bought Deal of Common Stock to $10 Million
  13. Cerecor Announces $8 Million Bought Deal Offering
  14. Do Insiders Own Lots Of Shares In Cerecor Inc. (NASDAQ:CERC)?
  15. Cerecor Receives Fast Track Designation from FDA for CERC-801 for the Treatment of PGM1 Deficiency
  16. Cerecor Announces CERC-301 Granted U.S. Patent
  17. Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor of Rockville, Maryland
  18. FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency
  19. FDA Grants Cerecor’s Three Substrate Replacement Therapies Orphan Drug Designation
  20. Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors